ALK and neuroblastoma: In neuroblastoma, where intact ALK is activated by specific point mutations rather than aberrant fusions, the first-generation ALK inhibitor crizotinib was found to exhibit modest efficacy in ALK-driven xenograft models10,22–26, and differential preclinical and clinical activity depending on the specific ALK driver mutations10,22,27,28.